ArticleAsia Pacific allergy2026
Current status of bronchial asthma and results of asthma control in patients after 3 months of treatment: A longitudinal follow-up study.
Article in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchial asthma (BA) is a chronic respiratory disease that significantly affects patients' quality of life if not well managed. The Global Initiative for Asthma (GINA) 2022 guidelines open a new, more effective direction in controlling asthma attacks for patients. Objective: The study was conducted to describe the current status of BA and the results of asthma control in patients after 3 months of treatment. Methods: A prospective longitudinal study was conducted on 47 patients over 12 years old with BA treated at the Department of Allergy, Immunology and Dermatology, Hospital E, from July 2023 to September 2024. The current study assessed BA control after treatment for patients according to GINA 2022 guidelines and the Asthma Control Test (ACT) score. Results: Before treatment, the majority of patients' BA attacks were severe (55.3%) with moderate obstructive ventilatory disorder (42.6%). After treatment, patients' asthma was completely controlled at 93.6%, while respiratory function was significantly improved. Conclusion: After treatment, patients' asthma was well controlled on all 3 assessment scales: GINA 2022 symptom control, ACT score, and respiratory function. Widespread application of GINA 2022 guidelines in BA control in Vietnam is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.